The DOI matches its Crossref record.
Estrogen Receptor Alpha (ER-α) and Beta (ER-β) mRNAs in Normal Ovary, Ovarian Serous Cystadenocarcinoma and Ovarian Cancer Cell Lines: Down-Regulation of ER-β in Neoplastic Tissues
Abstract
The prognosis in ovarian carcinoma, the most lethal of the gynecologic neoplasms, is poor and has changed little in the last three decades. Only a small number respond to antiestrogen therapy, although the classic estrogen receptor, ER-α, has been identified in ovarian surface epithelium, from which approximately 90% of ovarian cancers originate. We have previously shown that ER-β mRNA is most abundant in human fetal ovaries, suggesting that it might play an important role in ovarian development. Therefore, we investigated the mRNA levels of both ERs in normal ovaries, ovarian serous cystadenocarcinomas, granulosa cells from patients undergoing in vitro fertilization (IVF), the ovarian surface epithelium cell line IOSE-Van, and the ovarian cancer cell lines SKOV3, HEY and OCC1. Northern blots of normal and neoplastic ovaries were hybridized with an ER-β riboprobe that spans the A/B domain. We detected two major hybridizing bands at approximately 8 and 10 kb. An RNase protection assay using the same probe revealed a single band of the expected size. Hybridizing the same blot with an ER-α riboprobe showed a strong hybridizing band at approximately 6.5 kb. In ovarian cancer samples, ER-β mRNA level was decreased when compared to normal ovaries. Using 25 cycles of RT-PCR followed by Southern blotting, we found equal amounts of ER-α and -β mRNAs in normal ovaries in all age groups from 33 to 75 years; however, in ovarian cancer tissue, the level of ER-α mRNA was similar or slightly higher, comparable to 103 to 104 copies of plasmid DNA, but ER-β mRNA levels were markedly decreased. Granulosa cells from IVF patients expressed high levels of ER-β mRNA. The OSE cell line expressed low level of ER-α, detectable after 40 cycles of RT-PCR and no ER-β mRNA. SKOV3, showed low level of ER-α and β mRNAs, whereas OCC1 showed low level of ER-β and relatively high level of ER-α. HEY did not contain detectable amounts of either ER after 40 cycles of RT-PCR. We found no evidence of differential splicing or major deletions in almost the entire coding region of ER-β in either normal ovaries or tumor samples.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Estrogen Receptor Null Mice: What Have We Learned and Where Will They Lead Us?
Couse, J. F., & Korach, K. S. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0370 · Cited by 2,045
Ovarian Surface Epithelium: Biology, Endocrinology, and Pathology*
Auersperg, N., Wong, A. S. T., Choi, K.-C., Kang, S. K., & Leung, P. C. K. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.2.0422 · Cited by 1,046
Risch, H. A. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.23.1774 · Cited by 771
Menopausal Hormone Replacement Therapy and Risk of Ovarian Cancer
Lacey, Jr. (2002) · JAMA · doi:10.1001/jama.288.3.334 · Cited by 606
The Estrogen Receptor β Subtype: A Novel Mediator of Estrogen Action in Neuroendocrine Systems
Kuiper, G. G. J. M., Shughrue, P. J., Merchenthaler, I., & Gustafsson, J.-Å. (1998) · Frontiers in Neuroendocrinology · doi:10.1006/frne.1998.0170 · Cited by 439
Loss of ERβ expression as a common step in estrogen-dependent tumor progression
Bardin, A., Boulle, N., Lazennec, G., Vignon, F., & Pujol, P. (2004) · Endocrine-Related Cancer · doi:10.1677/erc.1.00800 · Cited by 417
Endogenous Hormones and Ovarian Cancer: Epidemiology and Current Hypotheses
Lukanova, A., & Kaaks, R. (2005) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.98.14.1 · Cited by 314
Estrogen Receptor β: An Overview and Update
Zhao, C., Dahlman-Wright, K., & Gustafsson, J.-Å. (2008) · Nuclear Receptor Signaling · doi:10.1621/nrs.06003 · Cited by 309
Immunocytochemical Localization of Estrogen Receptors α and β in the Human Reproductive Organs
Pelletier, G., & El-Alfy, M. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.12.7029 · Cited by 283
Lau, K.-M., Mok, S. C., & Ho, S.-M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5722 · Cited by 277
Estrogen receptors and human disease: an update
Burns, K. A., & Korach, K. S. (2012) · Archives of Toxicology · doi:10.1007/s00204-012-0868-5 · Cited by 275
Estrogen and its metabolites are carcinogenic agents in human breast epithelial cells
Russo, J., Hasan Lareef, M., Balogh, G., Guo, S., & Russo, I. H. (2003) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(03)00390-x · Cited by 252
Saunders, P. T. K., Millar, M. R., Williams, K., Macpherson, S., Harkiss, D., Anderson, R. A., Orr, B., Groome, N. P., Scobie, G., & Fraser, H. M. (2000) · Biology of Reproduction · doi:10.1095/biolreprod63.4.1098 · Cited by 175
Risks and benefits of dietary isoflavones for cancer
Andres, S., Abraham, K., Appel, K. E., & Lampen, A. (2011) · Critical Reviews in Toxicology · doi:10.3109/10408444.2010.541900 · Cited by 168
“Equal amounts of ER-α and ER-β mRNAs were reported in normal ovaries, whereas in human ovarian cancer, ER-β mRNA was markedly decreased (Brandenberger et al., 1998).”
BackgroundActivated Platelets Induce Estrogen Receptor β Expression in Endometriotic Stromal Cells
Zhang, Q., Ding, D., Liu, X., & Guo, S.-W. (2015) · Gynecologic and Obstetric Investigation · doi:10.1159/000377629 · Cited by 38
Metadata
- Authors
- Brandenberger, A. W., Tee, M. K., & Jaffe, R. B.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1998-03-01
- Volume
- 83
- Issue
- 3
- Pages
- 1025-1028
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2080321597
- Cited by
- 210
- References
- 0
- FWCI
- 15.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.